Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Favrille
Study ID
NCT00258336
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • autologous immunoglobulin idiotype-KLH conjugate vaccine — BIOLOGICAL
  • rituximab — BIOLOGICAL
  • sargramostim — BIOLOGICAL

Study Details

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving rituximab together with vaccine therapy and GM-CSF may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with vaccine therapy and GM-CSF works in treating patients with indolent B-cell non-Hodgkin's lymphoma.

Key Dates

Start date
Aug 31, 2004
Status verified
Aug 2008
Primary completion
Nov 30, 2009

Study Design

Enrollment
56 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Event-free survival by Kaplan-Meier

Locations (1)

FacilityCityStateZIPSite coordinators
Sarah Cannon Cancer Center at Centennial Medical CenterNashvilleTennessee37203
Clinical Trials Office - Sarah Cannon Cancer Center at Centenn
615-329-7274

Find similar trials in Nashville, TN

By research site
Sarah Cannon Cancer Center at Centennial Medical Center· Nashville, TN

Related Studies